The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study pr
about
The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study pr
description
scientific article published on 08 June 2020
@en
wetenschappelijk artikel
@nl
name
The SARS-CoV-2 Ivermectin Nava ...... ructured summary of a study pr
@en
The SARS-CoV-2 Ivermectin Nava ...... ructured summary of a study pr
@nl
type
label
The SARS-CoV-2 Ivermectin Nava ...... ructured summary of a study pr
@en
The SARS-CoV-2 Ivermectin Nava ...... ructured summary of a study pr
@nl
prefLabel
The SARS-CoV-2 Ivermectin Nava ...... ructured summary of a study pr
@en
The SARS-CoV-2 Ivermectin Nava ...... ructured summary of a study pr
@nl
P2093
P1433
P1476
The SARS-CoV-2 Ivermectin Nava ...... randomized control pilot trial
@en
P2093
Belen Sadaba
Carlota Dobaño
Felix Hammann
Francisco Carmona-Torre
Gabriel Reina
Gemma Moncunill
José Ramón Azanza
José Ramón Yuste
Juana Schwartz Mota
P356
10.1186/S13063-020-04421-Z
P577
2020-06-08T00:00:00Z